Dallas, Texas 10/24/2013 (Financialstrend) – AbbVie Inc (NYSE:ABBV) is an S&P 500 index tracked major drug manufacturer with a market capitalization of $75.8 billion. In October Morgan Stanley conducted an academic exercise where it stack ranked publicly traded companies by their forward yield, payout ratios and consistent income growth. AbbVie Inc came in fourth on the list with dividend yield of 3.31%, dividend payout ratio of 61.3% and profit margins going up by 27.5% over the past 12 months.
This represents the strong operational and financial strength of this drug manufacturing behemoth. In the past one year it has posted sales of $18.7 billion with net income coming in at $5.16 billion. Its sales had seen a 4.4% increase compared to previous quarter.
In order to sustain this return in value to its share holders, the drug maker had announced in late September that it had tied up with a Belgian drug manufacturing firm Ablynx. In a collaboration valued at $840 million, AbbVie had licensed the smaller firms arthritis target drug “ALX-0061”. It has agreed to pay the smaller drug manufacturer $175 million at the outset and will pay a reminder $665 million in the form of milestone payments on reaching certain predicated goals over the next couple of years as the target drug winds its way through the clinical trial process.
At close of business on October 23, the stock price was hovering around the $48.33 per share mark. This represented a 1.37% decrease over its previous day close. At these present valuations, the stock is trading just 2% lower than its 52 week high valuation and well on its way to meet the analyst determined price target of $49.23 per share. The strength of the stock rally can be gauged by the fact that it is trading at 16% above its 200 day moving average.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.